Summary
Chairpersons: Prof. Eva Prescott (ESC), Prof. William Wijns (ESC), Dr Isabelle Richard-Lordereau (Amgen), Dr Martin van Eickels (Bayer)
Objective of the workshop
To Discuss Aspects of the New ESC Stable Coronary Syndromes Guidelines.
|
Introduction |
Prof. Eva Prescott (ESC), Dr Martin Van Eickels (Bayer) & Dr Isabelle Lordereau-Richard (Amgen) |
|
13:00 - 13:15 |
Why a Change of Terminology to Chronic Coronary Syndromes? Prof. William Wijns, IE |
|
13:15 - 14:00 |
Keynote Lecture - The Future Role of Imaging in Preventing Cardiovascular Disease: “Prevention 1.5“ Prof. Valentin Fuster, USA (Zoom) |
|
SESSION 1 |
THE DIAGNOSTIC WORKUP OF PATIENTS WITH SUSPECTED CAD: A CHANGING LANDSCAPE Session Chairs: Prof. Juhani Knuuti, Maria Husseini (Philips), Philippe Karam (GE Healthcare) |
|
14:00 - 14:30 |
Pre-test Likelihood and Implications for Diagnostic Testing: New ESC Guidelines Recommendations Prof. Stephan Achenbach, DE |
|
14:30 - 15:00 |
Will Coronary CTA Replace Invasive Coronary Angiography? Prof. Jeroen Bax, NL |
|
15:00 - 15:30 |
Anatomical and Functional Evaluation: Many Options, Many Strategies Dr Victoria Delgado, NL |
|
15:30 - 16:00 |
Prof. David Newby, UK |
|
16:00 - 16:30 |
Diagnostic Workup for Suspected CAD: Industry Perspective Dr Friedrich Fuchs - Siemens, DE |
|
SESSION 2 |
PATIENTS WITH ANGINA AND SUSPECTED VASOSPASTIC OR MICROVASCULAR DISEASE Session Chairs: Prof. Colin Berry and Prof. Eva Prescott |
|
16:45 - 17:15 |
What Are the New ESC Guideline Recommendations? Prof. Javier Escaned, ES |
|
17:15 - 17:45 |
The Clinical Needs: Vasospastic and Microvascular Coronary Artery Disease Dr Yolande Appelman, NL |
|
17:45 - 18:15 |
The Medical Needs: Medical and Device Treatment Now and in the Future Prof. Filippo Crea, IT |
| 18:15 - 18:45 |
Industry View - Medical Therapy for Vasospastic and Microvascular CAD Dr. Li-Ming Gan -AstraZeneca, SE |
| 18:45 - 19:15 |
Industry View – Market Access Dr Nick West – Abbott, USA |
| SESSION 3 |
CHRONIC CORONARY SYNDROMES: CLINICAL IMPACT OF INTENSIFIED ANTI-THROMBOTIC THERAPIES Session Chairs: Prof. Steffen Massberg and Prof. William Wijns |
| 09:15 - 09:45 |
What Are the New ESC Guideline Recommendations for Anti-thrombotic Therapies? Prof. Emanuele Barbato, IT |
| 09:45 - 10:15 |
How to Balance Ischemic and Bleeding Risks: Clinical Impact of Intensified Anti-thrombotic Therapies Prof. Martine Gilard, FR |
| 10:15 - 10:45 |
Anti-thrombotic Therapy: Gaps in Knowledge and Upcoming Trials Prof. Sigrun Halvorsen, NO |
| 11:00 - 11:30 |
Anti-platelet Therapy: Reappraisal of Aspirin Prof. John W McEvoy, IE |
| 11:30 - 12:00 |
Industry View: What Are the New Drugs in the Pipeline? Dr Martin van Eickels - Bayer, DE |
Our mission: To reduce the burden of cardiovascular disease.